MBiotech Program News

15/06/2011 - 14:00 - MBiotech student publishes on clinical trial failure rate in Lymphoma

Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection Ms. Zoe Zhang conducted research on clinical trail failure rates in lymphoma while an MBiotech student.  Her work has now been published in a peer reviewed journal and is entitled "Clinical Trial Risk in Non-Hodgkin's Lymphoma:  Endpoint and Target...

09/08/2010 - 11:00 - Pharmacists get Schooled!

Associate Director Leigh Revers participates in the Canadian Society of Hospital Pharmacists' 63rd Summer Educational Sessions in Halifax, Nova Scotia as part of a presentation session entitled "The Paradox of Subsequent Entry Biologicals: A Non-Bioequivalent Generic" hosted by Janssen-Ortho Inc. Alongside other speakers from Amgen...

13/07/2010 - 10:00 - Part II: Subsequent entry biologics: Biosame or biodifferent?

MBiotech alumna Eva Furczon and Associate Director Leigh Revers recognized a need for today's generation of pharmacists to become better informed about the history of biologics and to learn how they differ from the more conventional small-molecule drugs that are prevalent in pharmacopeias.    ...

09/06/2010 - 10:00 - An introduction to biologics and biosimilars. Part I: Biologics: What are they and where do they come from?

Eva Furczon, a Master of Biotechnology student at the University of Toronto, and an intern at Roche Canada co-authored a paper with Associate Director Leigh Revers. The publication recently appeared in the 'Canadian Pharmacists Journal" (CPJRPC).   "An Introduction to Biologics" is a...

04/03/2010 - 10:26 - MBiotech Director published in 'Nature'

MBiotech Director published in 'Nature' Mar 04, 2010     Scott Prosser, Director of the MBiotech Program, publishes in 'Nature', one of the top two leading scientific journals in the world! Dr. Prosser and colleagues investigate a class of receptors called G-coupled protein receptors which constitutes the vast...

Pages